New biomarker advances cancer treatments

Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.A biomarker based on microbubbles has been used to evaluate the success of n

Updated on: November 21,2023 27

New biomarker advances cancer treatments

Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.A biomarker based on microbubbles has been used to evaluate the success of n

Updated on:November 21,2023 27

To stop spread of cancer, researchers target two signaling switches that trigger new blood vessel growth

byUniversity of East AngliaCredit: Unsplash/CC0 Public DomainHitting two targets at the same time may be the key to stopping the spread of aggressive cancers, according to new research from the

Updated on: January 08,2024 7

To stop spread of cancer, researchers target two signaling switches that trigger new blood vessel growth

byUniversity of East AngliaCredit: Unsplash/CC0 Public DomainHitting two targets at the same time may be the key to stopping the spread of aggressive cancers, according to new research from the

Updated on:January 08,2024 7

Helping blood cells regenerate after radiation therapy

Method boosts differentiation of stem cells into mature blood cell types, may help leukemia and lymphoma patients.Anne Trafton|MIT News OfficePublication Date:October 24, 2018 PRESS INQUIR

Updated on: October 11,2023 239

Helping blood cells regenerate after radiation therapy

Method boosts differentiation of stem cells into mature blood cell types, may help leukemia and lymphoma patients.Anne Trafton|MIT News OfficePublication Date:October 24, 2018 PRESS INQUIR

Updated on:October 11,2023 239

Why don't T cells destroy solid tumors during immunotherapy?

byUniversity of North Carolina Health Care3-D image of a T cell experiencing cell stress: endoplasmic reticulum (green), mitochondria (purple). Credit: Elizabeth Hunt, UNC School of MedicineThe

Updated on: January 08,2024 10

Why don't T cells destroy solid tumors during immunotherapy?

byUniversity of North Carolina Health Care3-D image of a T cell experiencing cell stress: endoplasmic reticulum (green), mitochondria (purple). Credit: Elizabeth Hunt, UNC School of MedicineThe

Updated on:January 08,2024 10

Novel tool helps differentiate between cancerous and healthy cells for AML

Spanish scientists have developed a new method to identify between cancerous and healthy cells for cases of acute myeloid leukaemia (AML).Researchers from Centre for Genomic Regulation (CRG), Spain, h

Updated on: October 31,2023 19

Novel tool helps differentiate between cancerous and healthy cells for AML

Spanish scientists have developed a new method to identify between cancerous and healthy cells for cases of acute myeloid leukaemia (AML).Researchers from Centre for Genomic Regulation (CRG), Spain, h

Updated on:October 31,2023 19

Discovery suggests new way to target mantle cell lymphoma

byWeill Cornell Medical CollegeThe interaction of two proteins required to regulate expression of key genes in the nucleus of mantle cell lymphoma. The red signals are generated at the interacti

Updated on: December 21,2023 11

Discovery suggests new way to target mantle cell lymphoma

byWeill Cornell Medical CollegeThe interaction of two proteins required to regulate expression of key genes in the nucleus of mantle cell lymphoma. The red signals are generated at the interacti

Updated on:December 21,2023 11

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on: October 10,2023 265

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on:October 10,2023 265

Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia

June 11, 2023Chris RyanThe novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who di

Updated on: October 24,2023 27

Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia

June 11, 2023Chris RyanThe novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who di

Updated on:October 24,2023 27

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

September 15, 2023Caroline SeymourTissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression

Updated on: October 11,2023 261

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

September 15, 2023Caroline SeymourTissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression

Updated on:October 11,2023 261

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21, 2020Nichole Tuckerhe feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demo

Updated on: October 24,2023 33

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21, 2020Nichole Tuckerhe feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demo

Updated on:October 24,2023 33

Researchers discover resistance to liver cancer treatment

byUniversity of Hawaii at ManoaCredit: Pixabay/CC0 Public DomainLiver cancer is the fourth deadliest cancer in Hawaiʻi, particularly affecting Native Hawaiian, Filipino and Japanese men. Patient

Updated on: October 31,2023 8

Researchers discover resistance to liver cancer treatment

byUniversity of Hawaii at ManoaCredit: Pixabay/CC0 Public DomainLiver cancer is the fourth deadliest cancer in Hawaiʻi, particularly affecting Native Hawaiian, Filipino and Japanese men. Patient

Updated on:October 31,2023 8

ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

September 12, 2022Lisa AstorResults from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and

Updated on: October 24,2023 42

ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

September 12, 2022Lisa AstorResults from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and

Updated on:October 24,2023 42